JP7725475B2 - シグマ－１受容体リガンド及びその使用 - Google Patents

シグマ－１受容体リガンド及びその使用

Info

Publication number
JP7725475B2
JP7725475B2 JP2022538109A JP2022538109A JP7725475B2 JP 7725475 B2 JP7725475 B2 JP 7725475B2 JP 2022538109 A JP2022538109 A JP 2022538109A JP 2022538109 A JP2022538109 A JP 2022538109A JP 7725475 B2 JP7725475 B2 JP 7725475B2
Authority
JP
Japan
Prior art keywords
hydrochloride
methyl
benzylpiperidin
aryl
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022538109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507508A (ja
JP2023507508A5 (https=
Inventor
ジャン－ジャック・ブルギニオン
マルティヌ・シュミット
ジャック・ブリカール
タンギー・モーリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ecole Pratique des Hautes Etudes SAS
Original Assignee
Ecole Pratique des Hautes Etudes SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecole Pratique des Hautes Etudes SAS filed Critical Ecole Pratique des Hautes Etudes SAS
Publication of JP2023507508A publication Critical patent/JP2023507508A/ja
Publication of JP2023507508A5 publication Critical patent/JP2023507508A5/ja
Application granted granted Critical
Publication of JP7725475B2 publication Critical patent/JP7725475B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022538109A 2019-12-19 2020-12-18 シグマ－１受容体リガンド及びその使用 Active JP7725475B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19306705.5 2019-12-19
EP19306705 2019-12-19
PCT/EP2020/086996 WO2021123145A1 (en) 2019-12-19 2020-12-18 Sigma-1 receptor ligands and uses thereof

Publications (3)

Publication Number Publication Date
JP2023507508A JP2023507508A (ja) 2023-02-22
JP2023507508A5 JP2023507508A5 (https=) 2023-12-26
JP7725475B2 true JP7725475B2 (ja) 2025-08-19

Family

ID=69232740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538109A Active JP7725475B2 (ja) 2019-12-19 2020-12-18 シグマ－１受容体リガンド及びその使用

Country Status (6)

Country Link
US (1) US20230049619A1 (https=)
EP (1) EP4077310B1 (https=)
JP (1) JP7725475B2 (https=)
CN (1) CN114981260A (https=)
CA (1) CA3157428A1 (https=)
WO (1) WO2021123145A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12612371B2 (en) 2019-12-19 2026-04-28 Universite De Strasbourg Sigma-1 receptor ligands and therapeutic uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011046745A (ja) 2003-01-31 2011-03-10 Vertex Pharmaceuticals Inc ジャイレース阻害剤およびその用途
JP2013526489A (ja) 2010-05-14 2013-06-24 中国人民解放軍軍事医学科学院毒物薬物研究所 １−［（４−ヒドロキシピペリジン−４−イル）メチル］ピリジン−２（１ｈ）−オン誘導体、その調製方法およびその使用
JP2016535040A (ja) 2013-10-29 2016-11-10 武田薬品工業株式会社 複素環化合物
WO2017222952A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2019068771A1 (en) 2017-10-04 2019-04-11 Esteve Pharmaceuticals, S.A. USE OF SIGMA RECEPTOR LIGANDS AGAINST AGE-RELATED COGNITIVE DISORDERS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB858792A (en) * 1958-02-10 1961-01-18 Sandoz Ltd New pyridazine derivatives and processes for their manufacture
GB0204252D0 (en) 2002-02-23 2002-04-10 Oxford Glycosciences Uk Ltd Novel compounds
US8404852B2 (en) * 2003-01-31 2013-03-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
ATE522249T1 (de) 2007-07-26 2011-09-15 Novartis Ag Organische verbindungen
WO2010131145A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
CA2761279A1 (en) 2009-05-20 2010-11-25 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
BR112014015197A8 (pt) 2011-12-21 2017-06-13 Novira Therapeutics Inc agentes antivirais de hepatite b

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011046745A (ja) 2003-01-31 2011-03-10 Vertex Pharmaceuticals Inc ジャイレース阻害剤およびその用途
JP2013526489A (ja) 2010-05-14 2013-06-24 中国人民解放軍軍事医学科学院毒物薬物研究所 １−［（４−ヒドロキシピペリジン−４−イル）メチル］ピリジン−２（１ｈ）−オン誘導体、その調製方法およびその使用
JP2016535040A (ja) 2013-10-29 2016-11-10 武田薬品工業株式会社 複素環化合物
WO2017222952A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2019068771A1 (en) 2017-10-04 2019-04-11 Esteve Pharmaceuticals, S.A. USE OF SIGMA RECEPTOR LIGANDS AGAINST AGE-RELATED COGNITIVE DISORDERS

Also Published As

Publication number Publication date
JP2023507508A (ja) 2023-02-22
US20230049619A1 (en) 2023-02-16
EP4077310B1 (en) 2024-05-01
WO2021123145A1 (en) 2021-06-24
EP4077310A1 (en) 2022-10-26
CN114981260A (zh) 2022-08-30
EP4077310C0 (en) 2024-05-01
CA3157428A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
TW202341983A (zh) 用於降解突變kras蛋白之化合物及其應用
CN103917534B (zh) 作为h3受体抑制剂的包含哌啶和哌嗪环的氨基甲酸酯/脲衍生物
JP2009503069A (ja) 三環式ベンゾイミダゾール類、および代謝性グルタミン酸塩受容体のモジュレータとしてのそれらの使用
ES2678770T3 (es) Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor
CN105175421A (zh) 用于合成选择性nk-3受体拮抗剂的中间体化合物及其用途
TW202019922A (zh) 醫藥化合物
WO2015088565A1 (en) P2x4 receptor modulating compounds and methods of use thereof
JP2017535545A (ja) 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物
FR2738819A1 (fr) Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
JP2025507852A (ja) 中環状または大環状ベンジル置換複素環誘導体および関連の使用
WO2019241751A1 (en) Ssao inhibitors and uses thereof
TW202336011A (zh) 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
KR20170097669A (ko) 항히스타민제로서의 신규한 벤즈이미다졸 유도체
JP7725475B2 (ja) シグマ－１受容体リガンド及びその使用
US11339151B2 (en) Aliphatic acid amide derivative
EP3891146B1 (en) Morpholinyl, piperazinyl, oxazepanyl and diazepanyl derivatives useful as o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
CA2750699A1 (en) Oxyindole derivatives with motilin receptor agonistic activity
JP7727635B2 (ja) シグマ－１受容体リガンド及びその治療的使用
KR20240115832A (ko) 헌팅턴병을 치료하기 위한 htt 조절제
CA3219801A1 (en) Substituted heterobicyclic derivatives as negative allosteric modulators of mglu7 receptor
TWI917344B (zh) 脂肪族酸醯胺衍生物
RU2817356C1 (ru) Соединение для разрушения андрогенового рецептора и его фармацевтическое применение
KR102217206B1 (ko) 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법
WO2025016273A1 (zh) 异喹啉衍生物、包含其的药物组合物以及它们的用途
KR20070036148A (ko) 신경병성 질환의 치료에 적합한 피페리딘, 피페라진 혹은모르폴린의 이량체 화합물 또는 그들의 ７-원 유사체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250806

R150 Certificate of patent or registration of utility model

Ref document number: 7725475

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150